A Novel First-in-Class Senolytic Therapy for Treating Various Chronic Inflammatory Skin Conditions
Time: 4:00 pm
day: Conference Day Two
Details:
- Chronic skin conditions like atopic dermatitis, psoriasis, and rosacea share an inflammatory environment that hinders healing
- Senescent cells contribute to this inflammation, driving immune responses that worsen disease progression and tissue degeneration, especially with aging
- Rubedo's Alembic platform identifies different types of senescent cells in diseased tissues. Using this platform, Rubedo develops selective senolytic drugs like RLS-1496, a first-in-class molecule targeting pathological skin senescent cells. This leading program, aimed at treating multiple dermatological conditions, is advancing into the clinical stage
